Lixing Chen went to his immigration appointment Sept. 15 just as he had the three times before, said his son, Andy Chen. Andy drove. When Chen went into the building for his appointment, Andy waited ...
Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (AKRO) to Peer Perform from Outperform following Novo Nordisk’s (NVO) plan to ...
Syracuse, N.Y. — Lixing Chen went to his immigration appointment Sept. 15 just as he had the three times before, said his son, Andy Chen. Andy drove. When Chen went into the building for his ...
Wolfe Research’s Andy Chen cut his rating on 89bio to 'Peer Perform' from 'Outperform' and did not assign a price target after the biotech firm agreed to a $3.5 billion takeover by Roche. 89bio’s ...
These are the most significant crypto developments in Latin America this week, from Brazil’s bold move to establish Belo ...
Here are six stories for the week of Sept. 21, 2025. Subscribe to get the Syracuse.com Exclusives newsletter delivered to ...